株式会社PRISM BioLab、13億円のシリーズC資金調達を実施 Published on: 9月 9, 2021PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today announced that it has raised a total of ¥1.3 billion in Series C funding on August 27. 詳細はこちら Read More
Japanese 
English 
